Introduction
Lung carcinoma represents the leading cause of malignancy-related mortality (1) . Therefore, much attention has been given to identify targets in the treatment of human lung cancer. One of the most frequently used targets of drug classes is the nuclear enzyme DNA topoisomerases II (2) . Topoisomerases are involved in several cellular events during the cell cycle such as DNA replication, transcription, recombination, and chromatid segregation. Among the topoisomerase II-affecting agents currently in clinical use is etoposide. Etoposide stabilizes topoisomease IIassociated double-strand DNA breaks by inhibiting the enzyme ability to ligate cleaved nucleic acid molecules. However, etoposide does not only inhibit the cell cycle but also affects other cellular functions. The etoposide targets are referred to as pre-targets when they correspond to plasma membrane and cytosolic components and to post-targets when they participate in gene regulation. In this regard, cellular perturbation caused by etoposide is also realized via initiation of apoptotic cell death (3) . Proteolytic activation of a cascade of caspases, a family of cysteine proteases that cleave their substrates after aspartate residues, is considered as the central element of the apoptotic machinery (4) . The cascade is started by auto-activation of initiator caspases, triggered either by ligand binding to death domain receptors (extrinsic pathway) or by cytosolic translocation of apoptogenic factors from mitochondria (intrinsic pathway). While the initiator caspase pro-caspase-8 mediates the receptor-induced apoptosis, release of cytochrome c from mitochondria leads to the activation of pro-caspase-9 in an apoptosome complex thereby mediating the mitochondrial-dependent pathway (5) . The subsequent proteolytic activation of executioner caspases, like pro-caspase-3, -6 and -7, results in the processing of a large variety of cellular substrates. Those substrates are activated, deactivated, or acquire new functions once cleaved by caspases and contribute to the characteristic morphological and biochemical changes that occur during apoptosis (6) .
However, caspase activation does not always result in the proteolysis of cellular determinants participating in cell death. Recently it has been shown that p120 RasGTPaseactivating protein (RasGAP), the main down-regulator of Ras GTPases family members (7) , is a substrate for caspases that differentially regulates apoptosis as caspase activity increases in cells (8) . Depending on the extent of its processing by caspases, RasGAP fragments stimulate survival signals at low levels of caspase activity but contribute to the execution phase of apoptosis when caspase activity is increased. The first cleavage of RasGAP occurs at position 455 at very low caspase activity (8) . The resulting N-terminal fragment triggers potent antiapoptotic mechanisms while the C-terminal fragment, containing the GTPase-binding function, leads to cell death in Ras-independent manner (8) . However, the anti-apoptotic properties of fragment N are dominant over the pro-apoptotic abilities of fragment C (8) . The N-terminal fragment mainly consists of Src homology (SH) domains which have an important dynamic role in recruiting GAPs to specific signalling complexes. Detailed investigation showed that RasGAP fragment N is a potent inhibitor of apoptosis down-stream of caspase activation as shown for caspase-9 (8) . Although fragment N does not contain the GTPase-activating domain, it effectively protects cells by initiating the chain of protein reactions involved in the Rasmediated pathway. The homology domain SH3, which is flanked by two SH2 domains, has been suggested to be involved in this process (9) . Subsequent activation of the phosphatidylinositol (PI)-3 kinase results in the phosphorylation of target proteins that contain pleckstrin homomolgy (PH) domains for binding to the inner plasma membrane. In RasGAP fragment N signalling, the serine/threonine kinase Akt (also known as protein kinase B) has been shown to be an effector of the PI-3 kinase pathway (10) via PDK1-mediated phosphorylation (11) . The PI-3 kinase-induced stimulation of Akt can contribute to cell survival through a number of mechanisms. This includes the inhibition of Bad activity (12) but also the suppression of Bax translocation to mitochondria (13) , blocking of pro-caspase-9 activation (14) and stimulation of the transcription factor NFκB activity via IKKα (15) . However, NFκB plays no role in the anti-apoptotic function of fragment N (10). At higher levels of caspase activity, the protective effect of RasGAP fragment N is abolished when fragment N is cleaved at position 157. This second cleavage event causes the formation of two N-terminal RasGAP fragments, named N1 and N2, which can effectively potentiate apoptotic cell death (8) .
The aim of the present study was to investigate the expression and cleavage pattern of RasGAP in a panel of lung cancer cell lines with different histology and sensitivity to anticancer treatment. Human lung carcinomas are broadly classified into non-small cell lung carcinomas (NSCLC) and small cell lung carcinomas (SCLC). This simplified grouping is based on the histology, biology and clinical behaviour of the tumours and their treatment options (16) . Both subtypes differ in their initial responsiveness to chemotherapeutic agents including etoposide (17) . While chemotherapy provides rather poor response rates in NSCLC patients with rare complete remissions, SCLC belong to the most drug-sensitive tumours. SCLC accounts for approximately 20 to 25% of all human lung cancers and, despite primary chemo-and radiosensitivity, SCLC bears the poorest prognosis of all lung cancer histologies due to fast tumour expansion, early metastasis and high incidence of relapse along with the subsequent development of therapy resistance (18) . Therefore, the resistance to treatment represents the major problem in the therapy of NSCLC and SCLC as well. The poor responsiveness to topoisomerase II inhibitors can lead to increased expression of topoisomerase II, lowered drug accumulation due to expression of membrane 'pump' proteins, altered cytotoxic signalling through stress-activated protein kinases and alterations in cell cycle proteins (19) . Previously it has been shown that the different susceptibility of SCLC and NSCLC to undergo apoptosis is related to the reduced drug response of malignant lung neoplasm (20) . While SCLC cells undergo cell death in caspase-dependent and -independent at Pennsylvania State University on February 23, 2013 http://carcin.oxfordjournals.org/ Downloaded from manner, the caspase-mediated pathway of apoptosis is inefficient in NSCLC mainly because of a defective translocation of active caspase-3 into the nucleus (21) . While the reduced nuclear localization of caspase-3 represents a key regulator of cell death influencing the responsiveness to chemotherapeutic agents in NSCLC, mechanisms involved in the acquired chemoresistance in SCLC are not yet fully understood.
The PI-3 kinase/Akt pathway has been found to play a significant role in the survival of experimental cancer cell lines including NSCLC and SCLC (22, 23) . Furthermore, altered expression of RasGAP is involved in tumorigenesis as well (24) that might consequently lead to an impaired controlling of p21 Ras signalling and other down-stream signalling pathways (7) . Based on these observations and that generation of the N-terminal RasGAP fragment participates in survival mechanisms via PI-3 kinase/Akt, we were interested to analyse the level of RasGAP and its N-terminal cleavage products in NSCLC and SCLC upon treatment of lung cancer cell lines with etoposide in relation to caspase activity and extent of apoptosis.
Material and methods

Antibodies and reagents
An antisera against the N-terminal moiety of RasGAP was produced in rabbits injected with a fusion protein consisting of a stretch of 6 histidine linked to amino acids 158-455 of RasGAP. This antigen was produced in BL21 (DE3) pLysS bacteria (Novagen, Madison, MI, USA) and purified by using a Ni-NTA affinity column (Qiagen AG, Basel, Switzerland), as follows. Bacteria corresponding to a 1 litre culture were lysed and sonicated in 40 ml of lysis buffer (50 mM HEPES, 500 mM NaCl, 10% Triton X-100, 20 mM Mg-Acetate, 0.5% β-mercaptoethanol, proteases inhibitor cocktail from Roche Diagn., 2 mg/ml lysozym, ~25 µg/ml DNaseI). The bacterial lysate was incubated for 45 min at 4°C with 1 ml of Ni-NTA beads, washed 3 times with 1 ml of lysis buffer containing 25 mM imidazole. The antigen was then eluted with 600 µl of lysis buffer containing 200 mM imidazole. The eluate was dialyzed two times against 5 litres PBS to remove imidazole and kept at -80°C until further use. Antibodies specific for RasGAP were further purified as follows. Three ml of the antisera diluted ten times in 10 mM Tris-HCl (pH 7.5) were loaded three times on a column containing 300 µl of Affigel 15 beads (Bio-Rad Laboratories, Hercules, CA, USA) on which 1.5 mg of the antigen was covalently coupled. The beads were washed with 6 ml 500 mM NaCl, 10 mM Tris-HCl (pH 7.5) and 6 ml 10 mM TrisHCl (pH 7.5). The antibody against RasGAP was eluted by using 3 ml of 100 mM glycine (pH 2.5) and recovered in 300 µl of 1 M Tris-HCl (pH 8.0). The antibody was stored at -20 °C until use. The antibody directed at the C-terminal moiety of RasGAP was from Alexis (ALX-210-781; Lausanne, Switzerland). Rabbit polyclonal antibodies against caspase-3, caspase-8, and caspase-9, or mouse monoclonal antibodies against cytochrome c and PARP (all are from BD Pharmingen, San Diego, CA, USA) were applied in PBS-T buffer (10 mM Na 2 HPO 4 , 140 mM NaCl, 0.15% Tween 20; pH 7.35). Equal protein loading was controlled by using the polyclonal antibody against glyceraldehydes-3-phosphate dehydrogenase (GAPDH; Trevigen, Gaithersburg, MD, USA). Bound antibodies were detected by horseradish peroxidaseconjugated goat anti-rabbit IgG or goat anti-mouse IgG antibodies (Pierce, Rockford, IL, USA), respectively, which were diluted in PBS-T supplemented with 2% non-fat dry milk.
Lung cancer cells were treated with etoposide (Vepesid  , VP16; Bristol-Myers Squibb, Bromma, Sweden), staurosporine (Roche Diagnostics, Mannheim, Germany) or the agonistic αFas monoclonal antibody (SY-001; Medical & Biological Laboratories Ltd., Nagoya, Japan) to induce cell death. The cell permeable peptide zVAD-FMK was applied as pan-caspase irreversible inhibitor, zDEVD-FMK for inhibiting caspase-3/-7 and zIETD-FMK for caspase-8, respectively (all are from Enzyme Systems Products, Livermore, CA, USA). The fluorogenic substrates Ac-DEVD-AMC and Ac-LEHD-AMC (Peptide Institute Inc., Osaka, Japan) were used for the determination of proteolytic caspase activities.
Cell lines, culture conditions and treatment
Human cell lines which were analysed correspond to non-small cell lung carcinoma (NSCLC: A549, H23, H125, H157, H661, U1752, U1810) or to small cell lung carcinoma (SCLC: H69, H82, H592, U1285, U1690, and U1285dox, a doxorubicin resistant variant of U1285). All cell lines of H denotation have the prefix National Cancer Institute [NCI] . Additionally, HeLa cells (human cervix carcinoma) and Jurkat cells (human T cell leukemia) were investigated as a nonlung cancer control. Lung cancer cell lines of U denotation are characterized earlier (25) , cell lines of A or H denotation, HeLa and Jurkat (TIB 152) are purchased from the ATCC cell bank (Manassas, VA, USA). Cells were cultured in RPMI 1640 medium supplemented with 7.5% heat-inactivated foetal bovine serum, 2 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin (Invitrogen Life Technology, Täby, Sweden) in 5% CO 2 atmosphere at 37°C.
Twenty four hours after seeding in culture dishes with fresh medium, cell were treated by adding etoposide (2.5 to 10 µM, 48 h), staurosporine (1 µM, 2 to 6 h) or the agonistic αFas monoclonal antibody (200 ng/ml, 24 h). Mock-treated cells of long-term experiments were initially seeded at less density to keep control cells at levels allowing exponential growth. The caspase inhibitory peptides zVAD-FMK, zDEVD-FMK and zIETD-FMK were used at 20 µM final concentration and added 1 h prior to treatment.
Cell death analysis
Apoptosis was analysed by investigation of nuclear alterations. An aliquot of the cells was resuspended in phosphate-buffered saline (PBS), spread on slides and allowed to air-dry. After fixation with acetone and staining with 1 µg/ml Hoechst 33342 in PBS (Molecular Probes Europe, Leiden, The Netherlands), 400 cells were assessed in each samples and scored as percentage of cells with fragmented and condensed nuclear morphology. In situ nuclear DNA fragmentation was determined by terminal deoxynucleotidyltransferase (TdT)-mediated dUTP nick end-labeling (TUNEL). Cells were prepared on slides, fixed with 3.7% paraformaldehyde (pH 7.4) and permeabilized with 0.1% Triton X-100 in PBS. After blocking with 3% bovine serum albumin in PBS and pre-incubation in TdT reaction buffer (pH 6.6), TUNEL reaction was carried out in a humidified chamber with 5 µM Fluorescein-12-dUTP, 50 µM dATP, 2.5 mM CoCl 2 and 25 units TdT (Roche Diagnostics) in TdT buffer at 37°C for 1 h. Thereafter, slides were co-stained with Hoechst 33342 in PBS and mounted with 50% glycerol in PBS. Samples were examined with an Olympus BX60 fluorescence microscope (excitation wavelength 365 nm) and images collected using the Hamamatsu digital camera ORCA II.
SubG1 DNA content was quantified by staining of DNA with propidium iodide (PI; Sigma, Deisenhofen, Germany) and subsequent flow cytometry. Briefly, PBS-rinsed cells were fixed with ice-cold 70% ethanol and incubated with PI solution (50 µg/ml PI, 5 mg RNase A, 0.1% Triton X-100, 0.1% sodium citrate, 0.1 mM Na 2 EDTA in PBS; pH 7.2) for 1 h at 4°C. DNA content was measured using the FACScan flow cytometer equipped with Cell Quest software (Becton Dickinson, San Josè, CA, USA). Additionally, amount of cells with loss of the plasma membrane integrity was counted in a hemacytometer after viability staining with 0.2% trypane blue in PBS. Another hallmark of cell death, the release of cytochrome c from mitochondria, has been quantified by immunoblot analysis of cytosolic protein preparations (see below).
In vitro caspase assay
Caspase activity was measured by cleavage of fluorogenic substrates specific for caspase-3-like proteases (Ac-DEVD-AMC) and caspase-9 (Ac-LEHD-AMC). Briefly, 2.5×10 5 cells were initially seeded. After treatment, cells were resuspended in 30 µl PBS and 25 µl were transferred to a 96-well plate. The remaining cell aliquot was kept for protein determination using the BCA protein assay (Pierce, Rockford, IL, USA). Enzyme reaction was performed at 37°C by adding 50 µl of either HEPES buffer (100 mM HEPES, 10% sucrose, 0.1% CHAPS, 5 mM DTT, 10 -6 % NP-40; pH 7.25) for caspase-3/-7 or MES buffer (100 mM MES, 10% sucrose, 0.1% CHAPS, 5 mM DTT, 10 -6 % NP-40; pH 6.5) for caspase-9 containing 30 µM of the respective peptide substrate. AMC liberation was monitored by a Fluoroscan II plate reader (Labsystems, Stockholm, Sweden) at 355 nm excitation and 460 nm emission, finally converted to pmol of AMC release per min and normalized per mg protein.
Protein extraction and immunoblot analysis
For preparation of cytosolic protein fraction, samples were incubated in isolation buffer (20 mM HEPES, 10 mM NaCl, 120 mM KCl, 1 mM KH 2 PO 4 , 1 mM MgCl 2 , 250 mM sucrose, 2 mM Na 2 ATP; pH 7.2) containing 10 µg digitonin per 1×10 6 cells and protease inhibitor cocktail (Roche Diagnostics). After 5 min of incubation at room temperature, lysates were cleared by centrifugation at 15,000×g for 10 min. In the case of total protein extraction, 1% Triton X-100 was added to the isolation buffer. Protein concentration was measured by the BCA protein assay (Pierce). For preparation of nuclei and mitochondria, differential centrifugation was applied using 250×g for nuclei separation and 4,000×g for mitochondria, respectively. Nuclei were subsequently purified by centrifugation at 3,000×g for 10 min through a density cushion containing 50% sucrose (w/v) in isolation buffer with MgCl 2 increased to 5 mM for nuclear stabilization. The resulting pellets of mitochondria and nuclei were washed twice in basic isolation buffer. All protein samples were mixed with 4×loading buffer (500 mM Tris-HCl, 40% glycerol, 8% SDS, 80 mM DTT, 4 mM Na 2 EDTA, 0.2% bromophenol blue; pH 7.4), boiled for 2 min and separated using SDS polyacrylamide gelelectrophoresis. Proteins of the analytic gel were blotted onto a nitrocellulose membrane in 10 mM CAPS buffer/20% methanol (pH 11.0) by the Bio-Rad wet blotting system (Bio-Rad Laboratories, Sundbyberg, Sweden). Thereafter, membrane was blocked with 6% non-fat dry milk in PBS-T and incubated with the respective antibody. Primary antibodies were detected by horseradish peroxidase-conjugated secondary antibodies and subsequently visualized by the ECL plus substrate solution (Amersham, Buckinghamshire, UK) according to manufacturer's instruction. The intensity of visualized signals was densitometrically analysed using the Aida evaluation software (Raytest, Straubenhardt, Germany).
Statistics
The significance of comparison of mean values was determined by the Student's t test. The one-way ANOVA procedure or the ANOVA analysis on Ranks for non-parametric groups was used for multiple comparisons. The correlation coefficient r of the linear regression analysis was tested using the two-sided test (SigmaStat software; Jandel Corp., San Rafael, CA, USA). All data reported are given as mean ± S.E.M. with p less than 0.05 as indicating a significant difference.
Results
RasGAP expression in human lung cancer cell lines
Immunoblot analyses of a panel of human lung cancer cell lines demonstrated that in basal conditions NSCLC cells show higher expression levels of p120 RasGAP compared to SCLC cells ( Figure 1A, B) . These results partially based on the fact that SCLC cell lines displayed increased processing of the full-length RasGAP protein into the N-terminal RasGAP fragment. As summarized in Table I , SCLC cells are characterized by an elevated level of spontaneous apoptosis as estimated by nuclear DNA fragmentation. While 9 ± 2% of apoptotic cells have been identified in SCLC cell lines, NSCLC cell lines showed nuclear features of apoptosis in less than 1% of cells (p<0.01 vs. SCLC). Subsequent linear regression analysis revealed a significant, positive correlation between the number of cells with spontaneous apoptosis and the relative cleavage of fragment N per RasGAP in human lung carcinomas ( Figure 1C) .
Cell death and caspase activation induced by etoposide in SCLC and NSCLC
Two human lung cancer cell lines with different levels of spontaneous apoptosis and initial formation of RasGAP fragment N were selected from the whole panel and investigated in detail: U1810 as an example for NSCLC and H82 for SCLC (Table I) . Both cell lines were subjected to treatment with increasing concentrations of etoposide (2.5 to 10 µM) for 48 h. In addition the broad spectrum protein kinase inhibitor staurosporine (1 µM, 2 to 6 h) and the agonistic αFas antibody (200 ng/ml, 24 h) have been used to induce cell death (see below). Figure 2 demonstrates that treatment of U1810 and H82 cells with etoposide resulted in a G2/M phase cell cycle arrest with a strong tendency of U1810 cells to accumulate already in the S phase at higher concentrations (≥5 µM) etoposide. The characterization of cell death triggered by etoposide and its influence by simultaneous inhibition of caspases using the broadrange inhibitory peptide zVAD-FMK (20 µM) is summarized in Table II . Taken together, these investigations revealed that loss of the plasma membrane integrity is a main feature of NSCLC U1810 cells undergoing etoposide-induced death, while the presence of apoptotic nuclei and subG1 DNA fragmentation are less prominent. However, a certain amount of U1810 was also characterized by typical apoptotic changes such as nuclear condensation, formation of membrane blebbing and cell shrinkage without trypane blue uptake ( Figure 2B ). The inhibition of caspases by zVAD-FMK did not prevent etoposide-induced apoptosis in U1810 cells. Rather it slightly shifted U1810 cells towards features of necrosis as shown by an increased leakage of the plasma membrane (Table II) . In contrast to U1810, SCLC H82 cells underwent a type of cell death more typical for apoptosis, which could be diminished following caspase inhibition by zVAD-FMK (Table II, Figure 2B ). In response to 5 µM etoposide, the amount of cells with apoptotic nuclear morphology and hypoploidy, as well as the number of trypane blue-positive cells and the extent of cytochrome c release, were clearly reduced in H82 cells treated with zVAD-FMK (Table II) . At higher concentration of etoposide (10 µM), zVAD-FMK still mediated the inhibition of both the formation of the subG1 peak and loss of cell viability, but the inhibition of cytochrome c release was nearly abolished (Table II) .
Although U1810 cells displayed some necrotic features in response to etoposide treatment, these cells exhibited a high DEVD-proteolytic activity of caspase-3-like proteases compared to H82 cells (Figure 3 ). Caspase-9 was similarly activated in both lung carcinoma cell lines as measured by LEHD-AMC proteolysis (Figure 3) . The corresponding cleavage of the prodomain for caspase-3 and caspase-9 was also clearly detected along with the mitochondrial release of cytochrome c ( Figure 2C ). Furthermore, treatment of U1810 cells with etoposide resulted in the cleavage of pro-caspase-8 which is not expressed in most SCLC cell lines including H82 ( Figure 2C) .
It has been shown previously that the typical for apoptosis nuclear changes (e.g. DNA ladder formation) are less prominent in NSCLC cell lines because of the failure of caspase-3 to relocalize to the nucleus (26) . Therefore, HeLa cells were analysed as a non-lung carcinoma cell line for comparison. In contrast to U1810 cells, HeLa cells display nuclear localization of active caspase-3 in response to etoposide despite a relative resistance towards the drug (27, 28) . In untreated conditions, the percentage of cells with apoptotic nuclei was comparable for HeLa and U1810 cells, but there were less HeLa cells taking up trypane blue compared to either U1810 or H82 cells (Table II) . The amount of HeLa cells with spontaneous apoptosis correlated with the initial cleavage of RasGAP into fragment N ( Figure 1C ). Although the etoposide-induced cell death in HeLa cells was characterized by clear apoptotic morphology and plasma membrane leakage that could be reduced by zVAD-FMK (Table II) Figure 2D , compare the first two lanes), indicating that certain caspase-independent cell death pathways can be activated in these cells.
Spontaneous and etoposide-induced processing of RasGAP in lung cancer
Total protein preparations as well as cytosolic subfractions were used for the detection of RasGAP and its caspase-generated proteolytic fragments. To compare the cleavage of RasGAP with another caspase substrate, cleavage of PARP was also investigated.
The generation of the N-terminal RasGAP fragment already occurs in presence of low caspase activities (8) . However, in vitro cell culturing entails several factors of stress that might influence the initial cleavage of RasGAP into fragment N. Therefore, the level of spontaneously generated RasGAP fragment N has been observed throughout all experiments performed with U1810, H82 and HeLa cells. The range of the relative amount of fragment N per RasGAP was found to be comprised between 0.1 to 0.5 for U1810, 0.25 to 1.0 for H82, and 0.25 to 1.2 for HeLa cells. The mean ratios of fragment N per full-length RasGAP are summarized in Figure 4 in comparison with the spontaneous cell death determined for each cell line. This revealed a positive correlation between relative fragment N generation and the amount of apoptotic cells but an inverse tendency to the amount of cells with necrotic morphology.
In order to evaluate a relationship between the formation of anti-apoptotic RasGAP fragment N and the susceptibility of lung cancer cells to apoptosis, cells were treated with different concentrations of etoposide (2.5 to 10 µM) for 48 h. Protein separation (total cellular proteins or cytosolic preparations) revealed that, in contrast to full-length RasGAP and fragment N2, the RasGAP fragment N is not localized within the cytosol ( Figure 5A ). Confirming the results presented in Figure 1B , immunoblot analyses demonstrated that RasGAP is always expressed at highest protein level in NSCLC U1810 cells and that the relative cleavage of RasGAP into fragment N in these cells is less induced than in H82 and HeLa cells. Generation of fragment N augmented in HeLa cells in response to increasing concentrations of etoposide (5-10 µM) ( Figure 5A ). This was not observed in both lung cancer cell lines.
As representatively shown on Figure 5A (left panel) etoposide induced the final cleavage of fragment N with formation of the pro-apoptotic RasGAP fragment N2 in NSCLC U1810 cells. This is in accordance with the elevated DEVD-proteolytic activity detected in U1810 cells, either directly in cell lysates (Figure 3) or indirectly by the assessment of PARP cleavage ( Figure 5B ). The caspase-mediated cleavage of RasGAP into fragment N2 was strongly reduced by broad-range inhibition of caspases using zVAD-FMK ( Figure 5A, left panel) . However, pan-caspase inhibitor zVAD-FMK did not influence the generation of RasGAP fragment N ( Figure 5A, right panel) .
Comparison of RasGAP cleavage mediated by treatment with etoposide, staurosporine or αFas
There was similar proteolytic activity of caspase-3-like proteases induced in H82 and U1810 cells by a 48 hours treatment with etoposide or a 4 hours exposure to staurosporine (Figure 3) . In contrast, staurosporine induced a much stronger caspase-3-like activity in HeLa cells compared to etoposide, consistent with the observation that these cells underwent massive apoptosis in response to staurosporine (91 ± 1% of apoptotic nuclei; n=4). Staurosporine is known to trigger cell death effectively in all lung carcinomas (26) , and treatment with this compound caused 27 ± 2% of apoptotic nuclei in U1810 and 40 ± 2% in H82 cells. In accordance with differences in caspase activation, staurosporine induced the cleavage of RasGAP into the N-and C-terminal fragments more efficiently than etoposide ( Figure 5A and 7A). The agonistic αFas antibody induced even less RasGAP processing into fragment N2 than etoposide in U1810 cells (Figure 6 ). No generation of fragment N2 could be detected in H82 cells treated with the αFas antibody (Figure 6 ), as expected since these cells lack pro-caspase-8 ( Figure 2) . In contrast to both lung carcinoma cell lines, Fas activation readily caused the cleavage of RasGAP into fragment N2 in HeLa and in Jurkat cells. This cleavage event was decreased by inhibition of caspase-3/-7 with DEVD-FMK and totally prevented by inhibition of caspase-8 using IETD-FMK ( Figure 6 ).
Analysis of total protein preparations and cytosolic subfractions revealed that RasGAP fragment N, in contrast to the full-length RasGAP protein, displayed a non-cytosolic location ( Figure 5A and 7A, B) . However, partial localization of fragment N in the cytosol fraction could be detected in certain conditions. Indeed, cytosolic detection of RasGAP fragment N has been observed after severe cell death induction by staurosporine ( Figure 7A ) and after etoposide-induced cell death with the concomitant inhibition of caspases in U1810 and HeLa cells ( Figure 7B ). Since the cleavage into fragment N2 was clearly reduced by zVAD-FMK, a possible explanation for the cytosolic detection of fragment N could be that cell death occurs along with the degradation of intracellular organelles, including nuclear disintegration or swelling and rupture of mitochondria. Consistent with this possibility is our observation that PARP, which is excluded from the cytosolic subfraction in control conditions, translocates to this particular fraction upon stimulation with either etoposide in the presence of caspase inhibitor or in the presence of staurosporine ( Figure 7C ).
Discussion
The family of p21 Ras proteins represents key components in the cellular signal transduction cascade leading to cell growth and differentiation. Function of p21 Ras family members has been linked to various processes that are important for cancer cell mitogenesis and metastasis (29) . The regulation of Ras activity involves conversion of the inactive Ras-GDP to active Ras-GTP form in which Ras GTPase-activating proteins (GAPs) contribute to the down-regulation of Ras by accelerating GTP hydrolysis of activated Ras. Five mammalian GAPs for Ras have been described including p120 RasGAP, the main GAP for this class of proteins (30) . In this study, we have demonstrated that RasGAP is differentially expressed in SCLC and NSCLC cells. While NSCLC cell lines showed a strong expression of RasGAP protein, the mean RasGAP level was markedly decreased in SCLC cells. Previous studies already revealed a putative role for RasGAP in tumorigenesis. Although data for GAPs are rare in human lung neoplasm, the oncogenic potential of RasGAP due to mutations within the SH2 region are demonstrated in other malignancies, as well as nuclear relocalization and alterations in the gene expression (24, 31) . In this regard, an inverse correlation between the level of RasGAP and the invasive potential and malignant phenotype has been described (32, 33) . Based on the poor clinical prognosis of SCLC (18) , our data additionally imply that low expression of RasGAP is associated with tumorigenesis and aggressive growth of SCLC. However, reduced availability of RasGAP could trigger two independent mechanisms. On one hand, it may be associated with the malignant behaviour of tumour cells, but, on the other hand, it may promote apoptotic cell death. In this context, Leblanc et al. revealed that RasGAP inhibition specifically induces apoptosis in tumour cells (34) , an observation that could be related to the fact that SCLC display low levels of RasGAP and are characterized by relatively high level of spontaneous apoptosis (35) . Furthermore, RasGAP deficiency also leads to neuronal cell death during embryonic development (36) . In contrast to SCLC, RasGAP is well expressed in NSCLC suggesting that its main action in these cells is to act as a negative regulator of Ras activity. Nevertheless, it has to keep in mind that in contrast to SCLC, NSCLC often bear oncogenic mutations in the ras genes (29) that render the Ras proteins insensitive to RasGAP (37) .
RasGAP is a dual function protein in the Ras signalling pathway because it also participates positively in cell signalling by mediating protein-protein interactions downstream of Ras-and Rho-dependent pathways (7, 38) . In the apoptotic process, the complex network of intracellular interactions via several protein domains in RasGAP is still intact despite its processing by caspases into several fragments. All generated forms of RasGAP have functional activity contributing to cell survival as well as to apoptosis (8) . While the N-terminal cleavage product of RasGAP of the first cleavage event (fragment N) has anti-apoptotic property, the resulting C-terminal fragment as well as both N-terminal fragments (N1 and N2), generated due to the second cleavage event of fragment N, potentiate apoptosis. Analysing of a panel of human lung cancer cell lines revealed differential levels of RasGAP expression in NSCLC and SCLC, partially as a consequence of increased spontaneous RasGAP cleavage in SCLC cell lines compared to NSCLC cell lines. This primary processing of RasGAP into fragment N correlated with the higher level of spontaneous apoptosis in SCLC, an observation that might explain the initial RasGAP cleavage in the absence of apoptotic stimulus. Although RasGAP fragment N can protect cells via PI-3 kinase/Akt signalling (10), it may in some circumstances promote apoptosis in a Rho-dependent manner (34) . Therefore and because of the parallel generation of the pro-apoptotic RasGAP fragment C, it is unclear if fragment N signalling is predominant in the molecular switch of SCLC cells. However, survival pathways initiated by RasGAP fragment N did overcome the opposite function of fragment C in vitro (8) and may participate in the constitutive activation of the Akt kinase observed in SCLC (39) and in the malignant phenotype of SCLC. The constitutive Akt stimulation has been shown to contribute to the transition of chemo-and radiosensitive SCLC cells to therapy-resistant tumours and transformation of classic (c-) SCLC to the insensitive variant (v-) SCLC (39) . Although Akt is also activated in response to many growth factors (IGF-I, EGF, bFGF and other) and active Akt kinase has been shown in nearly 70% of patients with NSCLC as well (40) , fragment Nmediated signalling represents an additional survival pathway in SCLC independent of the growth factor administration. Furthermore, we have revealed that RasGAP fragment N is not detectable in the cytosol whereas p120 RasGAP is. These findings raise the possibility that RasGAP proteins located at the plasma membrane and in other intracellular membranes are more accessible for proteolysis by caspases. Therefore, processing of RasGAP into fragment N would occur where RasGAP is actively regulating cell signalling. Alternatively, once formed, fragment N may immediately be targeted to non-cytosolic structures. There are peculiar cases, however, where fragment N is detected in the cytosolic fraction. For example, when caspases are inhibited in U1810 cells subjected to etoposide stimulation, a treatment that shifts the cells towards necrosis, fragment N and also PARP are detected in the cytosol. The increased generation of RasGAP fragment N might be one protective factor, especially in HeLa cells, that contributes to cell survival despite of intracellular necrotic changes.
The serine/threonine kinase Akt is phosphorylated and activated in response to apoptotic signals mediated by treatment of lung cancer cells with anti-cancer agents like etoposide (41) .
In our study we have demonstrated that generation of the Akt-stimulating RasGAP fragment N occurs after treatment of NSCLC and SCLC cells with etoposide as well. The formation of fragment N was relatively stable despite increasing concentrations of etoposide and always clearly detectable even with concomitant action of caspase-inhibitory peptides. This suggests a certain baseline proteolytic activity of caspases which can be reduced but not completely abolished by action of peptide inhibitors. This observation furthermore indicates the high susceptibility of RasGAP for caspase proteolysis at its first cleavage site.
In contrast to the first cleavage of RasGAP into fragment N, the second cleavage of RasGAP fragment N into fragment N2 depends on the increased caspase activity in NSCLC and SCLC cell lines. While the activity of caspase-3-like proteases is high in NSCLC U1810 cells that readily generate RasGAP fragment N2, SCLC H82 cells did not display such a high proteolytic activity and were less able to produce fragment N2. Consistent with the notion that caspase-3 activity is required for the generation of fragment N2 is the observation that HeLa cells induce high level of caspase-3-like activity in response to staurosporine and efficiently process RasGAP into fragment N2. In contrast to caspase-3-like proteases, a direct relationship between caspase-9 activity and terminal cleavage of RasGAP could not be drawn. The proteolytic rate of caspase-9 was low in comparison with caspase-3-like proteases in conditions where RasGAP was efficiently cleaved. One possible explanation for the differential activation of caspases could be that the continuous generation of RasGAP fragment N contributes, via PI-3 kinase/Akt stimulation, to phoshorylation and inactivation of caspase-9 (14) .
In comparison with etoposide, the cell death-inducing effect of staurosporine is more powerful although the anti-apoptotic RasGAP fragment N was generated as well. This might not only based on the second cleavage event, transformation of fragment N into the proapoptotic fragment N2, but also on the fact that staurosporine inhibits numerous kinases including PDK1 (42) , which are required for the entire Akt function (11) . Moreover, treatment with staurosporine rapidly induces mitochondrial dysfunction in tumour cells (26) that might additionally overcome the protective effect of RasGAP fragment N.
Recent studies have shown that stimulation of the PI-3 kinase/Akt pathway precedes the onset of apoptosis and cleavage of PARP by treatment with etoposide (41) . The clear formation of RasGAP fragment N in all cell lines studied and its further generation in response to etoposide might be one component contributing to cell survival via PI-3 kinase/Akt signalling and modulation of apoptosis. Although a potent anti-apoptotic effect has been described for RasGAP fragment N (8) and the Akt kinase pathways in general (22, 23, 39) , it is difficult to set the level of RasGAP fragment N detected in NSCLC and SCLC into direct relation with the level of spontaneous and etoposide-induced apoptosis. There are several important factors that might impair the protective effect of the N-terminal RasGAP fragment and subsequently change the apoptotic phenotype. Firstly, SCLC cell lines express lower levels of RasGAP protein compared with NSCLC. Consequently, the amount of fragment N generated by caspases is reduced despite higher levels of RasGAP processing. Secondly, strong stimulation of caspases in response to chemotherapeutic agents results in the simultaneous formation of RasGAP fragments (N1, N2 and C) that have the ability to potentiate apoptosis (8) . This could differentially affect the apoptotic responses in cells that do not activate caspases to the same extent, as observed in NSCLC and SCLC. Thirdly, Akt, the target anti-apoptotic kinase of the RasGAP fragment N pathway, is itself a caspase substrate (43) . Consequently an equilibrium between apoptotic and survival signals may rapidly be off-balanced by the negative cross-talks occurring between Akt and the caspases. Fourthly, the caspase-mediated cleavage of RasGAP reduces p120 RasGAP levels and this may weaken the negative regulation of p21 Ras proteins and consequently favour the development of malignant neoplasm (7, 29, 34) . Fifthly, lung cancer cell lines are characterized by several defects in the apoptotic machinery, like the inefficient translocation of key caspases, i.e. active caspase-3, into the nucleus in NSCLC (21) or the defective expression of caspase-8 in SCLC (44) . The insensitivity of lung cancer cells to Fas receptor stimulation correlated with the restricted cleavage of RasGAP into fragment N2.
Our findings indicate that spontaneous RasGAP cleavage into fragment N at low caspase activity and the reduced level of p120 RasGAP are associated with higher spontaneous apoptosis in SCLC compared to NSCLC. The anti-apoptotic fragment N might also contribute to the highly malignant and terminally therapy-resistant phenotype of SCLC. In response to etoposide and induction of higher caspase activity, lung cancer cells stably generate RasGAP fragment N which does have the potential to impair the complex network of apoptosis. However, compensatory mechanisms triggered by treatment with etoposide and distinct failures in the apoptotic machinery of lung cancer cells can differently influence the protective effect of the N-terminal RasGAP fragment in NSCLC and SCLC. ) (B, C) . The presence of RasGAP and its cleavage fragments (fragments N, N2 and C) (upper two panels), and PARP and its cleavage fragment (panel C) was visualized by Western blot. Spontaneous apoptosis index is calculated from percentages of cells with subG1 DNA fragmentation and TUNEL-positive nuclei. ACa, adenocarcinoma; LCa, large cell carcinoma; NSCLC, non-small cell lung carcinoma; SCCa, squamous cell carcinoma; SCLC, small cell lung carcinoma; n.d., not determined.
